ADDIA consortium is coordinated by Amoneta Diagnostics S.A.S., a French SME developing biomarker-based diagnostic
products for neurodegenerative diseases. For more information on Amoneta Diagnostics: www.amoneta-diagnostics.com
Firalis S.A. is the parent company of Amoneta Diagnostics and a participant of ADDIA project. Firalis is a leader SME in biomarker R&D, developing innovative diagnostic solutions, in particular for cardiovascular diseases and toxicities.
For more information on Firalis, please visit www.firalis.com
The ADDIA Consortium, started in Aug-2015 and funded by the E.C. within the franework of Horizon-2020/PHC-12 program, will realize an observational multicenter Proof-of-Performance (PoP) clinical trial, in participation of following clinical research centers:
For more information, do not hesitate to contact us.